Cargando…

Detection of somatostatin receptors in human osteosarcoma

BACKGROUND: The location of osteosarcoma in the metaphysis as well as the age of the patients during the most rapid tumour growth suggest that factors related to skeletal growth are involved in the pathogenesis of this tumour. In this aspect this study aims to detect somatostatin receptors in human...

Descripción completa

Detalles Bibliográficos
Autores principales: Ioannou, Markos, Papagelopoulos, Panayiotis J, Papanastassiou, Ioannis, Iakovidou, Ioanna, Kottakis, Stamatios, Demertzis, Nikolaos
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2546404/
https://www.ncbi.nlm.nih.gov/pubmed/18783595
http://dx.doi.org/10.1186/1477-7819-6-99
Descripción
Sumario:BACKGROUND: The location of osteosarcoma in the metaphysis as well as the age of the patients during the most rapid tumour growth suggest that factors related to skeletal growth are involved in the pathogenesis of this tumour. In this aspect this study aims to detect somatostatin receptors in human osteosarcomas and correlate this finding with the clinical outcome of the tumour. PATIENTS AND METHODS: Immunohistochemical staining for the presence of somatostatin receptors as well as overall survival and disease free survival rates were retrospectively studied in twenty-nine osteosarcoma patients. RESULTS: Four osteosarcomas with several aggressive biologic behaviour expressed somatostatin receptors. In these four young patients the event free rate was 0% and the overall survival rate was 50% at 4, 3 years. In contrast the event free survival rate of the twenty-five patients with negative somatostatin receptor status was 72% with an overall survival rate of 76% at 4,3 years. CONCLUSION: The present study demonstrates the existence of somatostatin receptors in human osteosarcoma. Tumours expressing somatostatin receptors seemed to be aggressive with a very low disease free and overall survival rate compared to osteosarcoma with negative receptor status.